HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.

Abstract
In schizophrenia, a psychiatric disorder that affects approximately 1% of the global population and is associated with substantial disability, a significant proportion of patients (usually estimated to be at least 30%) fail to respond to treatment, and many patients have difficulty continuing treatment because of side effects. At the time of publication, all available medications for schizophrenia targeted dopamine and other monoamine neurotransmitters. However, a substantial amount of research suggests that patients with schizophrenia have underlying deficits within the GABA neurotransmitter system. BL-1020, being developed by BioLineRx Ltd under license from Tel Aviv University Ltd and Bar-Ilan Research & Development Co Ltd, is a novel compound consisting of the well-established antipsychotic drug perphenazine and GABA. Preclinical studies of BL-1020 indicated that the compound penetrated the brain and was efficacious in rodents, with a significant reduction in side effects compared with the administration of perphenazine. BL-1020 was well tolerated in all clinical trials conducted, and clinically meaningful improvements were demonstrated in phase II trials in patients with schizophrenia. Further data from phase II and subsequent phase III trials will be required to derive conclusions for BL-1020 regarding overall efficacy.
AuthorsPaul B Fitzgerald
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 11 Issue 1 Pg. 92-100 (Jan 2010) ISSN: 2040-3429 [Electronic] England
PMID20047163 (Publication Type: Journal Article, Review)
Chemical References
  • Antipsychotic Agents
  • Receptors, GABA-A
  • perphenazine GABA ester
  • gamma-Aminobutyric Acid
  • Perphenazine
  • Dopamine
Topics
  • Animals
  • Antipsychotic Agents (adverse effects, pharmacokinetics, pharmacology, therapeutic use, toxicity)
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Contraindications
  • Dopamine (metabolism)
  • Drug Evaluation, Preclinical
  • Humans
  • Patents as Topic
  • Perphenazine (adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use, toxicity)
  • Quantitative Structure-Activity Relationship
  • Receptors, GABA-A (drug effects, metabolism)
  • Schizophrenia (drug therapy)
  • gamma-Aminobutyric Acid (adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: